Quantamental Intelligence

Closing the gap
before the market does.

We find stocks the market has priced wrong. Eight structured dimensions, one clear verdict. Independent research that tells you what to do — not just what happened.

Perception Gap Analysis Illustrative
Actual Quality Score 7.80/10
Perceived Quality Score 5.20/10

Perception Gap

+2.60

STRONG BUY Market undervalues fundamentals. Opportunity identified.

Proprietary

Multi-Factor Signal Engine

100%

Independent: No bank, no fund

Adaptive

Monitoring Cadence

Deep Dive

Research Format

What Makes This Different

Observers describe.
We prescribe.

Every published analysis includes a Prescription section: specific operational, capital allocation, or structural changes that would materially shift our rating, with an estimated valuation impact range.

This makes our research useful to two audiences: investors who want to act on the gap, and management teams who want to close it.

How we score and prescribe →

Example Prescription

+

Halt acquisitions for 18 months

Organic growth becomes visible at 6-7%. Compounder multiple becomes defensible.

+AUD 1.40 to +AUD 2.60
+

Refinance 2026 debt at current rates

WACC reduces ~80bps. Interest coverage ratio improves to 4.2x.

+AUD 0.70 on fair value floor
-

Continue current acquisition pace

Organic deterioration stays masked. Market re-rates toward sector median.

-AUD 1.50 to -AUD 2.20

Illustrative. Full prescriptions for subscribers only.

Intelligence Platform

What the system produces

Get full access →
Example Company EX · NYSE Technology Services

Last analysis: 2026-04-01 · Next review: adaptive

Quality Score

25/40

Gap Signal

+2.60

STRONG BUY
DATA SOURCES: Annual Reports ASX Filings Price Feed Insider Registry News Monitor Competitor Set

Signal Scorecard

Business Model
4/5
Management & Alignment
3/5
Client Quality
4/5
Organic Growth
2/5
Earnings Quality
3/5
Balance Sheet
4/5
Structural Risk
3/5
Valuation
2/5

Analyst Verdict

Market sentiment has overshot the fundamentals. The selloff reflects macro fears, not company-specific deterioration. Earnings quality is high, balance sheet is clean, and the moat is intact. At current pricing the market is handing you the premium for free.

Prescription

Initiate position in three tranches between €36 and €42. Set a thesis-change alert for Q3 margin data. Fair value range €48-57. Full prescription with four scenarios available to subscribers.

Intelligence tier required to view full analysis

Subscribe for Full Access

The Framework

Eight dimensions. One clear verdict.

Every company is scored across the same structured framework, without gut feel or narrative bias. Each dimension has defined criteria and contributes directly to the composite rating.

01

Earnings Quality

Cash conversion, accruals, and the reliability of reported profits. High-quality earnings are backed by free cash flow, not accounting adjustments.

02

Business Model Strength

Structural durability of the revenue model. Recurring revenue, switching costs, and pricing power all factor into this dimension.

03

Competitive Moat

Depth and durability of competitive advantages. Network effects, intangibles, cost advantages, and market position are assessed.

04

Management & Capital Allocation

Track record of capital deployment: M&A discipline, buybacks, dividends, insider ownership, and shareholder alignment.

05

Balance Sheet Health

Leverage, liquidity, and financial resilience. Strong balance sheets survive downturns and allow opportunistic action.

06

Growth Trajectory

Revenue, margin, and free cash flow trends over time. We distinguish between structural growth and cyclical tailwinds.

07

Valuation vs. Fundamentals

Fair value derived from DCF, multiples, and peer comparisons. We calculate a range, not a false-precision point estimate.

08

Perception Gap

The delta between how the market prices the company and what the fundamentals justify. Wide gaps create asymmetric opportunities.

Access

Choose your access level

One platform, three tiers. All include the same underlying intelligence.

Insights

€29/month

For investors who want the thesis and scorecard overview without the full model.

  • All published deep dives
  • Coverage scorecard summaries
  • Rating and gap signal per company
  • Substack digest (monthly)
Subscribe to Insights

Intelligence

€79/month

Full platform access. Every dimension, every signal, every prescription.

  • Everything in Insights
  • Full 8-dimension scorecard per company
  • Prescription with fair value scenarios
  • Bull / Bear / Non-Consensus Edge analysis
  • Management language semantic read
  • Perception gap signal history
  • Thesis change alerts
  • Insider transaction feed
Subscribe to Intelligence

Professional

€199/month

For serious investors who need the full picture plus custom alerting.

  • Everything in Intelligence
  • Portfolio quality overlay
  • Custom watchlist alerts via email
  • API access (beta)
  • Quarterly research call
  • Priority responses
Subscribe to Professional
📬
Free Substack digest — weekly coverage summaries, ratings, and market commentary.
Follow on Substack